Tool flags ‘lurking menace’ isomers before they become an expensive problem for drug developers

Researchers at AstraZeneca in the UK have developed a computational workflow to predict if a compound will exhibit atropisomerism,¹ an exotic form of chirality that can complicate drug development. The company has already incorporated the tool into its internal workflows.